It seems to be that the strategy has also levelled up!
Level 1 - PARTNERING OPPORTUNITY
AML we went from two costly trials focusing on R/R AML in which one would only likely result in a licensing deal. To one trial with a close alliance and now include cardio protect POC. AML 2-In-1 trial.
Level 2 - VALUE IMPROVEMENT + COST REDUCTION
The original plan was mBC for POC of cardio protect in limited patient population. We now have broad spectrum cancers + cardio protect + FTO POC. This takes addressable market from mBC to all cancers + all anthracycline treatments for those cancer. This is Triangle report best case + global use. 3-in-1 approach
Level 3 - FASTER APPROVAL PATHWAY
Fast track / Breakthrough and Priority review voucher, speeding up pathway to approval rather than end-to-end trials. Also, chance that cardiac and FTO data can be used for conditional approval for CDx?
It seems to be that the strategy has also levelled up!Level 1 -...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.77 |
Change
-0.095(5.09%) |
Mkt cap ! $315.0M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.86 | $1.76 | $347.3K | 192.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5612 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3568 | 1 |
View Market Depth
| Last trade - 15.59pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.78 |
Change
-0.095 ( 5.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.81 | $1.86 | $1.76 | 27553 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| RAC (ASX) Chart |